[{"address1": "1359 Broadway", "address2": "Suite 1710", "city": "New York", "state": "NY", "zip": "10018", "country": "United States", "phone": "212 433 3791", "website": "https://zentalis.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.", "fullTimeEmployees": 166, "companyOfficers": [{"maxAge": 1, "name": "Ms. Julie M. Eastland M.B.A.", "age": 60, "title": "CEO, President & Director", "yearBorn": 1964, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Mark  Lackner Ph.D.", "age": 56, "title": "Chief Scientific Officer", "yearBorn": 1968, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Wendy  Chang", "title": "Chief People Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Kimberly  Freeman", "title": "Chief Strategy Officer", "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Haibo  Wang", "title": "Chief Business Officer", "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 10, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1740787200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 1.79, "open": 1.75, "dayLow": 1.68, "dayHigh": 1.81, "regularMarketPreviousClose": 1.79, "regularMarketOpen": 1.75, "regularMarketDayLow": 1.68, "regularMarketDayHigh": 1.81, "payoutRatio": 0.0, "beta": 1.754, "forwardPE": -0.5070028, "volume": 937119, "regularMarketVolume": 937119, "averageVolume": 1799126, "averageVolume10days": 884450, "averageDailyVolume10Day": 884450, "bid": 1.77, "ask": 1.84, "bidSize": 8, "askSize": 9, "marketCap": 129978816, "fiftyTwoWeekLow": 1.61, "fiftyTwoWeekHigh": 16.265, "priceToSalesTrailing12Months": 1.927754, "fiftyDayAverage": 2.0369, "twoHundredDayAverage": 3.2602, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -198456176, "profitMargins": -2.45961, "floatShares": 44808227, "sharesOutstanding": 71811504, "sharesShort": 5326118, "sharesShortPriorMonth": 5187320, "sharesShortPreviousMonthDate": 1739491200, "dateShortInterest": 1741910400, "sharesPercentSharesOut": 0.0747, "heldPercentInsiders": 0.15463, "heldPercentInstitutions": 0.92801005, "shortRatio": 5.64, "shortPercentOfFloat": 0.1505, "impliedSharesOutstanding": 75719504, "bookValue": 4.73, "priceToBook": 0.38266385, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -165839008, "trailingEps": -2.33, "forwardEps": -3.57, "enterpriseToRevenue": -2.943, "enterpriseToEbitda": 1.066, "52WeekChange": -0.88778675, "SandP52WeekChange": 0.06429911, "quoteType": "EQUITY", "currentPrice": 1.81, "targetHighPrice": 10.0, "targetLowPrice": 2.2, "targetMeanPrice": 6.27, "targetMedianPrice": 6.0, "recommendationMean": 2.18182, "recommendationKey": "buy", "numberOfAnalystOpinions": 10, "totalCash": 371084000, "totalCashPerShare": 5.167, "ebitda": -186168992, "totalDebt": 42649000, "quickRatio": 7.133, "currentRatio": 7.322, "totalRevenue": 67425000, "debtToEquity": 12.649, "revenuePerShare": 0.949, "returnOnAssets": -0.23861, "returnOnEquity": -0.42828, "grossProfits": 67425000, "freeCashflow": -67098248, "operatingCashflow": -170860000, "grossMargins": 1.0, "ebitdaMargins": -2.76113, "operatingMargins": -1.71647, "financialCurrency": "USD", "symbol": "ZNTL", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "epsTrailingTwelveMonths": -2.33, "epsForward": -3.57, "epsCurrentYear": -2.25164, "priceEpsCurrentYear": -0.80385846, "fiftyDayAverageChange": -0.2269001, "fiftyDayAverageChangePercent": -0.111394815, "twoHundredDayAverageChange": -1.4502001, "twoHundredDayAverageChangePercent": -0.44481936, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "2.2 - Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1743203217, "regularMarketTime": 1743192000, "exchange": "NGM", "messageBoardId": "finmb_647536411", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": 1.1173174, "regularMarketPrice": 1.81, "shortName": "Zentalis Pharmaceuticals, Inc.", "longName": "Zentalis Pharmaceuticals, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1585920600000, "postMarketChangePercent": 0.0, "postMarketPrice": 1.81, "postMarketChange": 0.0, "regularMarketChange": 0.01999998, "regularMarketDayRange": "1.68 - 1.81", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 1799126, "fiftyTwoWeekLowChange": 0.19999993, "fiftyTwoWeekLowChangePercent": 0.12422356, "fiftyTwoWeekRange": "1.61 - 16.265", "fiftyTwoWeekHighChange": -14.455, "fiftyTwoWeekHighChangePercent": -0.8887181, "fiftyTwoWeekChangePercent": -88.77867, "earningsTimestamp": 1743019500, "earningsTimestampStart": 1746448200, "earningsTimestampEnd": 1746793800, "isEarningsDateEstimate": true, "displayName": "Zentalis Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-03-29"}]